Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470196 · ClinicalTrials.gov registry record · Phase 2
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
A Phase 2 study of Waldenstrom's Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT01470196 is a Phase 2 study of Waldenstrom's Macroglobulinemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 31 participants, below the 157-participant average among 5 other Waldenstrom's Macroglobulinemia trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01470196, a Phase 2 study of Waldenstrom's Macroglobulinemia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
Carfilzomib is a drug that has shown anti-tumor activity by inhibiting the proteasome within the cell, which is responsible for degrading or breaking down a wide variety of proteins. Carfilzomib has not been approved by the FDA. Rituximab and dexamethasone are often used to treat Waldenstrom's Macroglobulinemia (WM), alone or in combination with other drugs. Combinations with rituximab, dexamethasone and proteasome inhibitors, like carfilzomib, show high levels of activity in WM patients. In this research study, the investigators are testing the safety and efficacy of Carfilzomib when used along with Rituximab and Dexamethasone as a possible treatment for Waldenstrom's Macroglobulinemia.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Dexamethasone
- DRUG Carfilzomib
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01470196
The ClinicalTrials.gov registry entry for NCT01470196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 157-participant average among 5 other Waldenstrom's Macroglobulinemia trials with a reported enrollment target (80% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Waldenstrom's Macroglobulinemia appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.
NCT01470196 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01470196 about?
NCT01470196 is a clinical study titled "Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia". Carfilzomib is a drug that has shown anti-tumor activity by inhibiting the proteasome within the cell, which is responsible for degrading or breaking down a wide variety of proteins. Carfilzomib has not been approved by the FDA. Rituximab and dexamethasone are often used to treat Waldenstrom's Macr...
What is the current status of trial NCT01470196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2011-10. Estimated completion is 2016-09.
What conditions does trial NCT01470196 study?
This clinical trial studies the following conditions: Waldenstrom's Macroglobulinemia.
What interventions are being tested in trial NCT01470196?
The interventions under investigation include: Rituximab (DRUG), Dexamethasone (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01470196?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01470196 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom's Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
ACTIVE NOT RECRUITING · Phase 2
-
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
COMPLETED · Phase 2
-
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
ACTIVE NOT RECRUITING
-
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
COMPLETED · Phase 1
-
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.